|
1
|
Prostate (PRC) cancer factsheet.
http://www.encr.eu/images/docs/factsheets/ENCR_Factsheet_Prostate_2014.pdf04
17–2016
|
|
2
|
Wilt TJ, MacDonald R, Rutks I, Shamliyan
TA, Taylor BC and Kane RL: Systematic review: Comparative
effectiveness and harms of treatments for clinically localized
prostate cancer. Ann Intern Med. 148:435–448. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Guideline for the management of clinically
localized prostate cancer (2007). https://www.auanet.org/education/guidelines/prostate-cancer.cfmUpdated
2007. 04 17–2016
|
|
4
|
Heidenreich A, Bastian PJ, Bellmunt J,
Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T,
Zattoni F, et al: EAU guidelines on prostate cancer. Part II:
treatment of advanced, relapsing and castration-resistant prostate
cancer. Eur Urol. 65:467–479. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Norderhaug I, Dahl O, Høisaeter PA,
Heikkilä R, Klepp O, Olsen DR, Kristiansen IS, Waehre H and
Johansen TE Bjerklund: Brachytherapy for prostate cancer: A
systematic review of clinical and cost effectiveness. Eur Urol.
44:40–46. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zelefsky MJ, Hollister T, Raben A,
Matthews S and Wallner KE: Five-year biochemical outcome and
toxicity with transperineal CT-planned permanent I-125 prostate
implantation for patients with localized prostate cancer. Int J
Radiat Oncol Biol Phys. 47:1261–1266. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Roach M III, Hanks G, Thames H Jr,
Schellhammer P, Shipley WU, Sokol GH and Sandler H: Defining
biochemical failure following radiotherapy with or without hormonal
therapy in men with clinically localized prostate cancer:
Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int
J Radiat Oncol Biol Phys. 65:965–974. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sobin L and Wittekind C: Union for
international cancer control: TNM classification of malignant
tumours. 6th. Wiley; New York: 2002
|
|
9
|
Grimm PD, Blasko JC, Sylvester JE, Meier
RM and Cavanagh W: 10-year biochemical (prostate-specific antigen)
control of prostate cancer with (125)I brachytherapy. Int J Radiat
Oncol Biol Phys. 51:31–40. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zelefsky MJ, Kuban DA, Levy LB, Potters L,
Beyer DC, Blasko JC, Moran BJ, Ciezki JP, Zietman AL, Pisansky TM,
et al: Multi-institutional analysis of long-term outcome for stages
T1-T2 prostate cancer treated with permanent seed implantation. Int
J Radiat Oncol Biol Phys. 67:327–333. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Potters L, Morgenstern C, Calugaru E,
Fearn P, Jassal A, Presser J and Mullen E: 12-year outcomes
following permanent prostate brachytherapy in patients with
clinically localized prostate cancer. J Urol. 179(5 Suppl):
S20–S24. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Aaltomaa SH, Kataja VV, Lahtinen T,
Palmgren JE and Forsell T: Eight years experience of local prostate
cancer treatment with permanent I125 seed brachytherapy-morbidity
and outcome results. Radiother Oncol. 91:213–216. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hinnen KA, Battermann JJ, van Roermund JG,
Moerland MA, Jürgenliemk-Schulz IM, Frank SJ and van Vulpen M:
Long-term biochemical and survival outcome of 921 patients treated
with I-125 permanent prostate brachytherapy. Int J Radiat Oncol
Biol Phys. 76:1433–1438. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Henry AM, Al-Qaisieh B, Gould K, Bownes P,
Smith J, Carey B, Bottomley D and Ash D: Outcomes following
iodine-125 monotherapy for localized prostate cancer: The results
of leeds 10-year single-center brachytherapy experience. Int J
Radiat Oncol Biol Phys. 76:50–56. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Crook J, Borg J, Evans A, Toi A,
Saibishkumar EP, Fung S and Ma C: 10-year experience with I-125
prostate brachytherapy at the Princess Margaret Hospital: Results
for 1,100 patients. Int J Radiat Oncol Biol Phys. 80:1323–1329.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Marshall RA, Buckstein M, Stone NN and
Stock R: Treatment outcomes and morbidity following definitive
brachytherapy with or without external beam radiation for the
treatment of localized prostate cancer: 20-year experience at mount
sinai medical center. Urol Oncol. 32(38): e1-72014.
|
|
17
|
Dickinson PD, Malik J, Mandall P, Swindell
R, Bottomley D, Hoskin P, Logue JP and Wylie JP: Five-year outcomes
after iodine-125 seed brachytherapy for low-risk prostate cancer at
three cancer centres in the UK. BJU Int. 113:748–753. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hayashi N, Izumi K, Sano F, Miyoshi Y,
Uemura H, Kasuya T, Mukai A, Hata M and Inoue T: Ten-year outcomes
of I125 low-dose-rate brachytherapy for clinically
localized prostate cancer: A single-institution experience in
japan. World J Urol. 33:1519–1526. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
McLaren DB, Kerr G, Law AB, Brush JP,
Keanie J, Malik J, Keough W, Ronaldson T, Lee J and Kehoe T: The
importance of prostate-specific antigen (PSA) nadir and early
identification of PSA relapse after 10 years of prostate iodine 125
seed brachytherapy in edinburgh. Clin Oncol (R Coll Radiol).
27:519–526. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Taira AV, Merrick GS, Butler WM, Galbreath
RW, Lief J, Adamovich E and Wallner KE: Long-term outcome for
clinically localized prostate cancer treated with permanent
interstitial brachytherapy. Int J Radiat Oncol Biol Phys.
79:1336–1342. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nanda A, Chen MH, Moran BJ, Braccioforte
MH and D'Amico AV: Cardiovascular comorbidity and mortality in men
with prostate cancer treated with brachytherapy-based radiation
with or without hormonal therapy. Int J Radiat Oncol Biol Phys.
85:e209–e215. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Margel D, Urbach DR, Lipscombe LL, Bell
CM, Kulkarni G, Austin PC and Fleshner N: Metformin use and
all-cause and prostate cancer-specific mortality among men with
diabetes. J Clin Oncol. 31:3069–3075. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Taira AV, Merrick GS, Galbreath RW, Morris
M, Butler WM and Adamovich E: Metformin is not associated with
improved biochemical free survival or cause-specific survival in
men with prostate cancer treated with permanent interstitial
brachytherapy. J Contemp Brachytherapy. 6:254–261. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shetti MB, Merrick GS, Butler WM,
Galbreath R, Torlone A, Lief JH, Adamovich E and Wallner KE: The
impact of diabetes mellitus on survival in men with clinically
localized prostate cancer treated with permanent interstitial
brachytherapy. Am J Clin Oncol. 35:572–579. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wright JL, Plymate SR, Porter MP, Gore JL,
Lin DW, Hu E and Zeliadt SB: Hyperglycemia and prostate cancer
recurrence in men treated for localized prostate cancer. Prostate
Cancer Prostatic Dis. 16:204–208. 2013.PubMed/NCBI
|
|
26
|
Meng Y, Liao YB, Xu P, Wei WR and Wang J:
Statin use and mortality of patients with prostate cancer: A
meta-analysis. Onco Targets Ther. 9:1689–1696. 2016.PubMed/NCBI
|
|
27
|
Kuban DA, Levy LB, Potters L, Beyer DC,
Blasko JC, Moran BJ, Ciezki JP, Zietman AL, Zelefsky MJ, Pisansky
TM, et al: Comparison of biochemical failure definitions for
permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys.
65:1487–1493. 2006. View Article : Google Scholar : PubMed/NCBI
|
